HomeComparePETQ vs ARCC

PETQ vs ARCC: Dividend Comparison 2026

PETQ yields 6.46% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PETQ wins by $6.1K in total portfolio value· pulled ahead in Year 2
10 years
PETQ
PETQ
● Live price
6.46%
Share price
$30.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.6K
Annual income
$973.55
Full PETQ calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — PETQ vs ARCC

📍 PETQ pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPETQARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PETQ + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PETQ pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PETQ
Annual income on $10K today (after 15% tax)
$548.74/yr
After 10yr DRIP, annual income (after tax)
$827.52/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, PETQ beats the other by $826.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PETQ + ARCC for your $10,000?

PETQ: 50%ARCC: 50%
100% ARCC50/50100% PETQ
Portfolio after 10yr
$27.6K
Annual income
$487.35/yr
Blended yield
1.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

PETQ
No analyst data
Price Target
$31.00
+0.1% upside vs current
Range: $31.00 — $31.00
Altman Z
2.5
Piotroski
8/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PETQ buys
0
ARCC buys
0
No recent congressional trades found for PETQ or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPETQARCC
Forward yield6.46%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$30.6K$24.5K
Annual income after 10y$973.55$1.14
Total dividends collected$8.1K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst price target$31.00$21.88

Year-by-year: PETQ vs ARCC ($10,000, DRIP)

YearPETQ PortfolioPETQ Income/yrARCC PortfolioARCC Income/yrGap
1$11,346$645.58$11,373$532.74$27.00ARCC
2← crossover$12,824$684.53$12,608$279.46+$216.00PETQ
3$14,445$723.13$13,809$142.90+$636.00PETQ
4$16,218$761.23$15,042$72.20+$1.2KPETQ
5$18,151$798.73$16,341$36.27+$1.8KPETQ
6$20,258$835.49$17,732$18.18+$2.5KPETQ
7$22,547$871.43$19,231$9.10+$3.3KPETQ
8$25,032$906.47$20,851$4.55+$4.2KPETQ
9$27,725$940.52$22,605$2.28+$5.1KPETQ
10$30,639$973.55$24,504$1.14+$6.1KPETQ

PETQ vs ARCC: Complete Analysis 2026

PETQStock

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

Full PETQ Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this PETQ vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PETQ vs SCHDPETQ vs JEPIPETQ vs OPETQ vs KOPETQ vs MAINPETQ vs HTGCPETQ vs GBDCPETQ vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.